Literature DB >> 10421502

Malignant pleural mesothelioma: a problematic review.

T L Moskal1, J D Urschel, T M Anderson, J G Antkowiak, H Takita.   

Abstract

Malignant pleural mesothelioma is a rare tumor that has been difficult to study. Because of disappointing treatment results, malignant pleural mesothelioma has remained an area of active research and development. A clinicopathologic review is performed in light of several problematic issues involving diagnosis, staging, natural history, and treatment. Multimodality treatment with surgery followed by adjuvant local and systemic therapy remains the most optimal therapy. Many controversial issues still exist in the treatment of malignant pleural mesothelioma. In the ensuing years newer staging systems, better preoperative staging, newer experimental therapies, and the localization of patients at expert centers will undoubtedly have an impact on disease management.

Entities:  

Mesh:

Year:  1998        PMID: 10421502     DOI: 10.1016/s0960-7404(98)00019-x

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

Review 1.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

2.  Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.

Authors:  Zhiwen Liu; Julius Klominek
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

3.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

4.  Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?

Authors:  Andrew J Drain; Kourosh Saeb-Parsy; Amit K Shah; D Rassl; Andrew J Ritchie
Journal:  J Cardiothorac Surg       Date:  2006-11-01       Impact factor: 1.637

5.  The cytotoxic effect of magainin II on the MDA-MB-231 and M14K tumour cell lines.

Authors:  Radu Anghel; Daniela Jitaru; Laurenţiu Bădescu; Magda Bădescu; Manuela Ciocoiu
Journal:  Biomed Res Int       Date:  2013-10-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.